{'52WeekChange': -0.3638562,
 'SandP52WeekChange': 0.0644362,
 'address1': 'Paasheuvelweg 25a',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 39.5,
 'askSize': 900,
 'averageDailyVolume10Day': 436412,
 'averageVolume': 594371,
 'averageVolume10days': 436412,
 'beta': 1.230252,
 'beta3Year': None,
 'bid': 39.34,
 'bidSize': 800,
 'bookValue': 6.666,
 'category': None,
 'circulatingSupply': None,
 'city': 'Amsterdam',
 'companyOfficers': [],
 'country': 'Netherlands',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 40.65,
 'dayLow': 39.3,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -12.187,
 'enterpriseToRevenue': 236.496,
 'enterpriseValue': 1477865344,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 52.50686,
 'fiftyTwoWeekHigh': 76.687,
 'fiftyTwoWeekLow': 36.2,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 34321892,
 'forwardEps': -2.13,
 'forwardPE': -18.52582,
 'fromCurrency': None,
 'fullTimeEmployees': 248,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.07797,
 'heldPercentInstitutions': 0.9593,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/uniqure.com',
 'longBusinessSummary': 'uniQure N.V., a gene therapy company, engages in the '
                        'development and commercialization of treatments for '
                        'patients suffering from genetic and other diseases in '
                        'the Netherlands. Its lead program is Etranacogene '
                        'dezaparvovec (AMT-061), which is in Phase III HOPE-B '
                        'pivotal trial for the treatment of hemophilia B. The '
                        'company also engages in developing AMT-130, a gene '
                        'therapy that is in Phase I/II clinical study for the '
                        "treatment of Huntington's disease; AMT-060, which is "
                        'in Phase I/II clinical trial for the treatment of '
                        'hemophilia B; AMT-180, an one-time '
                        'intravenously-administered gene therapy candidate, '
                        'which is in preclinical stage for the treatment of '
                        'hemophilia A; and AMT-190, an IV-administered '
                        'adeno-associated virus 5-based gene therapy for the '
                        'treatment of Fabry disease. In addition, it engages '
                        'in developing AMT-150, a gene therapy candidate for '
                        'the treatment of Spinocerebellar Ataxia Type 3 '
                        'disease. The company has collaboration and license '
                        'agreements with Bristol Myers-Squibb Company; Gen-X; '
                        'and Synpromics Limited. uniQure N.V. was founded in '
                        '1998 and is headquartered in Amsterdam, the '
                        'Netherlands.',
 'longName': 'uniQure N.V.',
 'market': 'us_market',
 'marketCap': 1748062208,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_171029664',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -124428000,
 'nextFiscalYearEnd': 1640908800,
 'open': 40.33,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '31 20 240 6000',
 'previousClose': 40.71,
 'priceHint': 2,
 'priceToBook': 5.919592,
 'priceToSalesTrailing12Months': 279.7347,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 40.65,
 'regularMarketDayLow': 39.3,
 'regularMarketOpen': 40.33,
 'regularMarketPreviousClose': 40.71,
 'regularMarketPrice': 40.33,
 'regularMarketVolume': 691743,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 44299600,
 'sharesPercentSharesOut': 0.0837,
 'sharesShort': 3706384,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 4497906,
 'shortName': 'uniQure N.V.',
 'shortPercentOfFloat': 0.0936,
 'shortRatio': 4.43,
 'startDate': None,
 'strikePrice': None,
 'symbol': 'QURE',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -2.987,
 'twoHundredDayAverage': 56.280937,
 'volume': 691743,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.uniqure.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '1105 BP'}